Clinical Study
Effects of Low-Dose Testosterone Undecanoate Treatment on Bone Mineral Density and Bone Turnover Markers in Elderly Male Osteoporosis with Low Serum Testosterone
Table 1
Characteristics of the patients at the entry (means ± SD).
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
TU: testosterone undecanoate; BMI: body mass index; FPG: plasma glucose; HbA1c: glycosylated hemoglobin A1c; TC: total cholesterol; TG: triglyceride; HDL-CH: high-density lipoprotein cholesterol; LDL-CH: low-density lipoprotein cholesterol; PSA: prostate specific antigen; fPSA: free prostate specific antigen; BMD: bone mineral density; TT: total testosterone; fT: free testosterone; E2: estradiol; BAP: bone-specific alkaline phosphatase; uNTX/Cr: urine N-telopeptide of type 1 collagen/creatinine. |